An ASX listed health care sector player Alterity Therapeutics Limited (ASX:ATH) was listed on ASX in 2000 and engaged in developing the therapies for the people having neurodegenerative diseases. The company was primarily known as Prana Biotechnology and was incorporated in Melbourne in 1997. Alterity Therapeutics has its offices in the United States, San Francisco, Australia and Melbourne. The lead candidate of the company, PBT434, is the first new generation product of small molecules that are designed to reduce the pathological proteins (α-synuclein and tau proteins) aggregation implicated in neurodegeneration.

Load More
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK